Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Status:
Active, not recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The main purpose of this protocol is to estimate the percentage of patients with intermediate
risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years
after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field
radiation therapy. The hypothesis being studied is that this treatment will result in more
than 80% of patients being alive and free of disease three years after starting treatment.